

Jean-Luc Teillaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9308798/publications.pdf>

Version: 2024-02-01

67
papers

3,399
citations

186209

28
h-index

149623

56
g-index

95
all docs

95
docs citations

95
times ranked

4393
citing authors

#	ARTICLE	IF	CITATIONS
1	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 832-844.	2.5	564
2	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 355-366.	0.6	284
3	Differential Modulation of Stimulatory and Inhibitory Fc γ 3 Receptors on Human Monocytes by Th1 and Th2 Cytokines. <i>Journal of Immunology</i> , 2001, 166, 531-537.	0.4	215
4	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. <i>Blood</i> , 2010, 116, 926-934.	0.6	183
5	Structural Bases of Fc γ Receptor Functions. <i>Immunological Reviews</i> , 1992, 125, 49-76.	2.8	137
6	Impact of Glycosylation on Effector Functions of Therapeutic IgG. <i>Pharmaceuticals</i> , 2010, 3, 146-157.	1.7	132
7	Regulated Expression and Inhibitory Function of Fc γ RIIb in Human Monocytic Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 5082-5089.	1.6	120
8	Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc γ RIIIA/CD16. <i>British Journal of Haematology</i> , 2008, 140, 635-643.	1.2	115
9	Fc γ R: The key to optimize therapeutic antibodies?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 26-33.	2.0	86
10	Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes. <i>Journal of Immunology</i> , 2005, 175, 2278-2285.	0.4	82
11	Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. <i>Oncogene</i> , 1999, 18, 551-557.	2.6	80
12	The identification of monoclonal class switch variants by sib selection and an ELISA assay. <i>Journal of Immunological Methods</i> , 1984, 74, 307-315.	0.6	79
13	The Fc Receptor for IgG Expressed in the Villus Endothelium of Human Placenta Is Fc γ RIIb2. <i>Journal of Immunology</i> , 2001, 166, 3882-3889.	0.4	77
14	Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fc γ R functions. <i>Clinical Immunology</i> , 2006, 118, 170-179.	1.4	77
15	Fc γ RII expression in resting and activated B lymphocytes. <i>European Journal of Immunology</i> , 1989, 19, 1379-1385.	1.6	76
16	Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc γ RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1481-1491.	1.9	63
17	Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. <i>FEBS Journal</i> , 2009, 276, 3881-3893.	2.2	58
18	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. <i>Frontiers in Immunology</i> , 2017, 8, 830.	2.2	54

#	ARTICLE	IF	CITATIONS
19	Human Macrophages and Dendritic Cells Can Equally Present MART-1 Antigen to CD8+ T Cells after Phagocytosis of Gamma-Irradiated Melanoma Cells. <i>PLoS ONE</i> , 2012, 7, e40311.	1.1	50
20	Monoclonal antibodies as a tool for phylogenetic studies of major histocompatibility antigens and ? 2-microglobulin. <i>Immunogenetics</i> , 1982, 15, 377-384.	1.2	48
21	Molecular aspects of human Fc γ 3R interactions with IgG: Functional and therapeutic consequences. <i>Immunology Letters</i> , 2006, 106, 111-118.	1.1	47
22	A human anti α CD monoclonal antibody selected for enhanced Fc γ 3RIII engagement clears RhD⁺ autologous red cells in human volunteers as efficiently as polyclonal anti α CD antibodies. <i>British Journal of Haematology</i> , 2008, 141, 109-119.	1.2	47
23	Combining IR spectroscopy with fluorescence imaging in a single microscope: Biomedical applications using a synchrotron infrared source (invited). <i>Review of Scientific Instruments</i> , 2002, 73, 1357-1360.	0.6	42
24	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 626776.	2.2	39
25	A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms. <i>PLoS ONE</i> , 2011, 6, e26469.	1.1	38
26	A novel subset of NK cells expressing high levels of inhibitory Fc γ 3RIIB modulating antibody-dependent function. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1511-1520.	1.5	36
27	A New Set of Monoclonal Antibodies Against Human Fc γ 3RII (CD32) and Fc γ 3RIII (CD16): Characterization and Use in Various Assays. <i>Hybridoma</i> , 1997, 16, 519-528.	0.9	35
28	Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. <i>Frontiers in Immunology</i> , 2021, 12, 698604.	2.2	35
29	Selective PCR Amplification of Functional Immunoglobulin Light Chain from Hybridoma Containing the Aberrant MOPC 21-Derived V λ by PNA-Mediated PCR Clamping. <i>BioTechniques</i> , 1999, 26, 818-822.	0.8	34
30	Generation of phagocytic MAK and MAC-DC for therapeutic use. <i>Experimental Hematology</i> , 1999, 27, 751-761.	0.2	28
31	In vivo induction of functional Fc γ 3RI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). <i>British Journal of Haematology</i> , 1998, 100, 550-556.	1.2	27
32	Detection and quantification of secreted soluble Fc γ 3RIIA in human sera by an enzyme-linked immunosorbent assay. <i>Journal of Immunological Methods</i> , 1993, 166, 1-10.	0.6	24
33	Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. <i>Immunology Letters</i> , 1999, 65, 143-151.	1.1	24
34	Modulation of tumor immunity by therapeutic monoclonal antibodies. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 111-124.	2.7	24
35	Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. <i>Pathology and Oncology Research</i> , 2005, 11, 92-97.	0.9	22
36	Recombinant interleukin 2-activated natural killer cells regulate IgG2a production. <i>European Journal of Immunology</i> , 1990, 20, 1781-1787.	1.6	21

#	ARTICLE	IF	CITATIONS
37	Activating and inhibitory Fc γ 3 receptors in immunotherapy: being the actor or being the target. Expert Review of Clinical Immunology, 2009, 5, 735-747.	1.3	17
38	Evaluation of circulating tumor necrosis factor- β in patients with gynecological malignancies. International Journal of Cancer, 1991, 48, 375-378.	2.3	15
39	Regulation of IgG production by suppressor Fc γ 3RII+ T hybridomas. European Journal of Immunology, 1990, 20, 55-61.	1.6	14
40	Involvement of FcR+ T cells and of IGG-BF in the control of myeloma cells. Molecular Immunology, 1990, 27, 1209-1217.	1.0	14
41	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fc γ 3RIIB. Journal of Immunology, 2008, 181, 5350-5359.	0.4	13
42	Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid Fc γ 3RII Expressing Tumor Cells. Immunobiology, 1992, 185, 415-425.	0.8	11
43	Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?. Frontiers in Immunology, 2017, 8, 950.	2.2	11
44	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood, 2022, 139, 1160-1176.	0.6	11
45	Effect of zinc on human IgG1 and its Fc γ 3R interactions. Immunology Letters, 2012, 143, 60-69.	1.1	10
46	Fc γ 3R expressed on T-cell hybrids: Specificity, behavior and relationship with Ia antigens. Cellular Immunology, 1981, 63, 349-361.	1.4	9
47	Molecular heterogeneity of murine IgG-BF. Molecular Immunology, 1986, 23, 1183-1191.	1.0	9
48	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	2.2	9
49	Analysis of DR-like molecules on a marmoset Epstein-Barr virus-induced cell line using a monomorphic anti-human HLA-DR monoclonal antibody. European Journal of Immunology, 1982, 12, 446-448.	1.6	8
50	Soluble Fc γ 3 Receptor, Fc γ 3RIIa2, is Present in Two Forms in Human Serum and is Increased in Patients: With Stage C Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1997, 26, 317-326.	0.6	8
51	Regulatory effects of IgG-BF on hybridoma B cells. Molecular characterization of variant cell lines. Molecular Immunology, 1988, 25, 1133-1142.	1.0	7
52	A tumor specific single chain antibody dependent gene expression system. Oncogene, 1999, 18, 559-564.	2.6	7
53	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1561-1572.	2.0	6
54	Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use. British Journal of Haematology, 2001, 114, 671-680.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. <i>Molecular Immunology</i> , 1990, 27, 1219-1228.	1.0	4
56	High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 3-15.	2.0	4
57	Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?. <i>Cancer Cell</i> , 2022, 40, 240-243.	7.7	4
58	Le mot des coordinateurs. <i>Medecine/Sciences</i> , 2009, 25, 995-996.	0.0	3
59	Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy. <i>Cancer Cell</i> , 2016, 29, 771-773.	7.7	3
60	Involvement of human membrane-associated complement components in the rosette formation between Marmoset red blood cells and human leukocytes. <i>Cellular Immunology</i> , 1982, 66, 254-268.	1.4	2
61	Molecular characterization of two Ia-like antigens in marmoset. <i>Immunogenetics</i> , 1984, 19, 155-161.	1.2	2
62	In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc γ 3RII+T cell hybridoma and by immunoglobulin G-binding factors. <i>Immunologic Research</i> , 1992, 11, 296-304.	1.3	2
63	Epitope Mapping and Tight-Binding Inhibition with Monoclonal Antibodies Directed against <i>Escherichia coli</i> Glucosamine 6-phosphate Synthase. <i>Archives of Biochemistry and Biophysics</i> , 1995, 324, 391-400.	1.4	2
64	A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy. <i>Oncolimmunology</i> , 2020, 9, 1770565.	2.1	2
65	BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells. <i>Science Advances</i> , 2022, 8, eabl4363.	4.7	2
66	Can NK Cells Play a Role in Anti-CD20 Immunotherapy for CLL Patients?.. <i>Blood</i> , 2007, 110, 3103-3103.	0.6	0
67	R603: A New Low Dose Efficient Anti-CD20 Immunotherapy for CLL Patients ?. <i>Blood</i> , 2008, 112, 4155-4155.	0.6	0